CerSci Therapeutics
Dallas
About CerSci Therapeutics
CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $13.9M
- Funding stage: M&A
- Last round: Series A (Mar 2019)
- Website: cersci.com
Industries & Categories
Biopharma, Biotechnology, Life Science, Neuroscience, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cersci-therapeutics-80913 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.